VarCov Co’s Prime Medicine PRME Stock Holding History

VarCov Co’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-41,964	Closed	-$146K	–	510
2026 Q1	$146K	Buy	+41,964	New	+$160K	0.05%	355

Other funds holding PRME

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VarCov Co's PRME Position: Q2 2026 in Review

VarCov Co sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 41,964 shares — an estimated $146K sold.

VarCov Co first reported a position in PRME in Q1 2026 and held it in 1 quarter. The position peaked at $146K in Q1 2026. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

VarCov Co reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
VarCov Co sold 41,964 Prime Medicine shares in Q2 2026, an estimated $146K.
VarCov Co first reported a position in Prime Medicine in Q1 2026 and held it in 1 quarter.
VarCov Co's Prime Medicine position peaked at $146K in Q1 2026.
186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.